Other News To Note
Wednesday, February 8, 2012
Amicus Therapeutics Inc., of Cranbury, N.J., received a two-year, $186,000 grant from the Muscular Dystrophy Association (MDA) to evaluate the effect of the pharmacological chaperone AT2220 (duvoglustat HCl) on immunogenicity related to the enzyme replacement therapy (ERT) alglucosidase alfa, the only approved treatment for Pompe disease. As part of the MDA grant, Amicus will investigate the ability of AT2220 to mitigate ERT-specific immunogenicity from blood samples obtained in the ongoing open-label Phase II drug-drug interaction study of AT2220 co-administered with ERT in individuals with Pompe disease and from normal donors.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.